Page 1099 - Hematology_ Basic Principles and Practice ( PDFDrive )
P. 1099
Chapter 60 Myelodysplastic Syndromes 969.e13
532. Bryan J, Kantarjian H, Prescott H, et al: Clofarabine in the treatment of 535. Clinical Trials (PDQ®) - National Cancer Institute [Internet]. [cited
myelodysplastic syndromes. Expert Opin Investig Drugs 23(2):255–263, 2015 Mar 20];Available from: <http://www.cancer.gov/clinicaltrials/
2014. search/view?cdrid=737176&version=Patient>.
533. Roberts DA, Wadleigh M, McDonnell AM, et al: Low efficacy and high 536. Gleason MK, Ross JA, Warlick ED, et al: CD16xCD33 bispecific
mortality associated with clofarabine treatment of relapsed/refractory killer cell engager (BiKE) activates NK cells against primary MDS and
acute myeloid leukemia and myelodysplastic syndromes. Leuk Res MDSC CD33+ targets. Blood 123(19):3016–3026, 2014.
39(2):204–210, 2015. 537. Grant S: New agents for AML and MDS. Best Pract Res Clin Haematol
534. Ipilimumab in treating patients with relapsed or refractory high-risk 22(4):501–507, 2009.
myelodysplastic syndrome or acute myeloid leukemia—Full Text
View—ClinicalTrials.gov [Internet]. [cited 2015 Mar 20]; Available
from: <https://clinicaltrials.gov/ct2/show/NCT01757639>.
